CeGaT, a global provider of genetic diagnostics and sequencing services based in Tübingen, Germany, is celebrating several events: CeGaT turns 15 years old today. The inauguration of the extension triples the size of the CeGaT building. And furthermore, the family-run company is again fully owned by the founders since April 1, 2024.

Since its foundation in 2009, CeGaT has undergone an impressive development and now has the largest sequencing capacity of privately run laboratories worldwide.

CeGaT invited all employees, friends, family, and guests of honor from politics, business, and science to a festive event to celebrate the anniversary and inauguration. The event’s highlight was the speeches by Peter Gabriel, Tübingen’s construction mayor Cord Soehlke, the architects Dannien and Roller, and a patient, followed by an exclusive tour of the new building. On arrival on the roof terrace, the guests enjoyed the view of the Swabian Alb. Looking to the future, Dr. Dirk Biskup, managing director and co-founder of CeGaT, emphasized optimistically: "Moving into the new building on our company’s 15th birthday gives us several reasons to celebrate! We are very proud of our great team and our achievements. Moreover, we are very well positioned to meet future challenges in this tough market."

A 15-year success story

Founded by Dr. Dr. Saskia Biskup and Dr. Dirk Biskup, CeGaT revolutionized genetic testing by combining next-generation sequencing with human genetic diagnostics for the first time. This innovative approach was recognized in 2011 with the "Deutscher Gründerpreis" (German Founder Award) and in 2014 with an EU Innovation Award. "Our vision (and we are still a long way from achieving it) is to make genetic diagnostics and high-throughput sequencing at the highest level available and affordable for everyone," says Dr. Dr. Saskia Biskup, managing director and co-founder of CeGaT. “This includes preventive diagnostics as well as patient diagnosis or the examination of specific samples for researchers.” In addition to genetic diagnostics, CeGaT works for researchers, biotech companies, and "big pharma" by offering high-quality sequencing and an all-around service. By continuously expanding its range of services and investing in ever-newer and modern technologies, CeGaT is positioning itself as a long-term partner at the forefront of biomedical diagnostics and research.

New building: focus on sustainability and a feel-good atmosphere

CeGaT has expanded its site with a sustainably conceptualized new building to accommodate the company’s growth. The L-shaped extension offers modern office and laboratory space on three floors and fulfills key aspects of sustainability using recycled concrete, renewable raw materials, and geothermal and photovoltaic systems. The implementation of these measures exceeds the standards of the KFW 40 environmental norm and thus contributes to a considerable reduction in CO2 emissions.

The new building is connected to the existing building, the construction of which began almost exactly 11 years ago, with the official ground-breaking ceremony on April 16, 2013. "The fact that we have had to triple our office and laboratory space in just seven years exceeds all expectations. This step is a testament to our unique team’s exceptional commitment and performance, for which I am very grateful. It’s great to have all our employees back at one location," says Dr. Dirk Biskup.

CeGaT completely family-owned since April 1, 2024

The international medical technology company B. Braun and CeGaT have ended their collaboration. The background is that both partners will pursue different strategic directions in the future despite a long-standing and trusting collaboration. As a result, B. Braun has sold its shares in CeGaT GmbH to Saskia and Dirk Biskup as of April 1, 2024. This means that the Tübingen-based biotechnology company is now once again fully owned by the two founders.

Über die CeGaT GmbH

CeGaT GmbH, founded in Tübingen, Germany, in 2009, is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.

The company combines the latest sequencing technology with its many years of medical expertise – dedicated to identifying the genetic cause of disease and supporting patient care. For research and the pharmaceutical industry, CeGaT offers a broad portfolio of sequencing services and tumor analyses. CeGaT generates the data basis for clinical studies and medical innovations, driving science forward with own findings. The owner-managed company stands for independence, an extensive personal customer service, and premium quality.

Firmenkontakt und Herausgeber der Meldung:

CeGaT GmbH
Paul-Ehrlich-Str. 23
72076 Tübingen
Telefon: +49 7071 56544 260
http://www.cegat.com

Ansprechpartner:
Christfried Dornis
Marketing & Communication
Telefon: +49 (7071) 56544-261
E-Mail: christfried.dornis@cegat.de
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel